EUCTR2007-003406-10-FR进行中（未招募）1 期
A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Both male and female patients able and willing to provide written informed consent
- •Age 18-75 years (inclusive) at visit 1
- •Signed informed consent (approved by Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures
- •Patients with CHD or CHD risk equivalent based on NCEP ATPIII, eg. atherosclerosis, diabetes or >20% 10 year risk of CHD events
- •HDL-C <50 mg/dL (<1.3 mmol/L) at visit 1
- •Triglycerides level =400 mg/dL (<4.5 mmol/L) at visit 1
- •Appropriately treated with statin and/or other LDL lowering drug to a stable accepted LDL level (<100 mg/dL [<2.6 mmol/L] unless taking maximimum tolerated doses of therapy) based on their medical condition
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Females who are pregnant or breast feeding
- •Women of child bearing potential (women who are not surgically sterile or post-menopausal defined as amenorrhea for > 12 months or amenorrhea for 6 – 12 months and FSH = 45U/L)
- •Concomitant treatment with niacin, fibrates, bile acid sequestrants, rimonabant or CETP therapy. Treatment with ezetimibe and fish oil derivatives will be permitted.
- •Concomitant treatment with any drug other than RO4607381 administered for the purpose of increasing levels of HDL C.
- •Patients with clinically apparent liver disease, eg, jaundice, choleastasis, hepatic synthetic impairment, or active hepatitis
- •Hepatic transaminase, alkaline phosphatase or total bilirubin levels >1.5 times the ULN at Visit 1
- •Unexplained creatine phosphokinase levels >3 times the ULN at visit 1
- •Uncontrolled blood pressure: Systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg at screening or any other pre-randomization visit
- •Serum creatinine > 2.2 mg/dL at Visit 1.
- •Recent (within 3 months before Visit 1) clinically significant coronary events, including unstable angina, myocardial infarction, angioplasty, or coronary artery bypass graft.
- •Recent (within 3 months before Visit 1) transient ischemic attacks or cerebrovascular accident
- •Poorly controlled diabetes mellitus (HbA1c >10%) due to inability to comply with recommended diabetes management
- •Severe anemia defined as hemoglobin (Hb)< 10g/dL
- •Patients with homozygous familial hypercholesterolemia
- •Current or history of drug or alcohol abuse within 5 years of Visit 1
- •History of malignancy (except for curatively treated basal cell or squamous cell carcinoma of the skin) during the 3 years prior to Visit 1
- •Any clinically significant medical condition that could interfere with the conduct of the study
- •Presence of any abnormality on a laboratory evaluation performed prior to randomization that is considered by the investigator to be clinically important.
- •History of receiving R04607381 in a clinical trial in the previous 12 months
- •Subjects previously exposed to torcetrapib
- •Use of any investigational drug within 1 month before Visit 1
- •Subjects who have received an investigational drug or device within 1 month of visit 1, or who expect to participate in any other investigational drug or device study during the conduct of this trial
- •Inability or unwillingness to comply with the protocol requirements, or deemed by the investigator to be unfit for the study
研究者
相似试验
进行中（未招募）
不适用
A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - N/AEUCTR2007-003406-10-ATF.Hoffmann-La Roche Ltd.450
进行中（未招募）
不适用
A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - NDEUCTR2007-003406-10-ITROCHE450
进行中（未招募）
不适用
A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of dalcetrapib by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents - dal-VESSEPatients with Coronary Heart Disease (CHD) or CHD Risk Equivalents.MedDRA version: 9.1Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2007-003406-10-DEF. Hoffmann-La Roche Ltd.450
进行中（未招募）
不适用
A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kidney Disease Undergoing Percutaneous Coronary InterventioEUCTR2007-002208-17-NLDanube Pharmaceuticals60
进行中（未招募）
1 期
A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyMedDRA version: 12.1Level: LLTClassification code 10064060Term: Multiple system atrophyMultiple system atrophyEUCTR2009-018157-23-ATAstraZeneca AB120